Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms.

At this time point, CART3-mCALR cell-treated mice exhibited a significant reduction in tumor burden compared with mock-treated animals, achieving complete tumor clearance in one mouse and demonstrating a strong trend toward increased infiltration of human T lymphocytes in both the spleen and bone marrow ( figure 3D ).

also in 5,725 other papers